Common Equity (Annual)

Common Equity: The sum of all common equity items.

BioCryst Pharmaceuticals, Inc. (BCRX) had Common Equity of $-119.15M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$874.84M
Net Income	$263.86M
Cost of Goods Sold	$19.07M
Gross Profit	$855.76M
Operating Expenses	$533.85M
Operating Income	$340.99M
Non-Operating Income/Expense	$-73.60M
Pre-Tax Income	$267.39M
Normalized Pre-Tax Income	$267.39M
Income after Taxes	$263.86M
Income from Continuous Operations	$263.86M
Consolidated Net Income/Loss	$263.86M
Normalized Income after Taxes	$263.86M
EBIT	$340.99M
EBITDA	$338.05M
Weighted-Average Shares Outstanding (Basic)	209.89M
Weighted-Average Shares Outstanding (Diluted)	218.58M
Earnings per Share (EPS) (Basic)	$1.26
Earnings per Share (EPS) (Diluted)	$1.21
Balance Sheet Financials
Current Assets	$404.35M
Property, Plant, and Equipment	$8.78M
Long-Term Assets	$109.81M
Total Assets	$514.16M
Current Liabilities	$196.07M
Long-Term Debt	$428.67M
Long-Term Liabilities	$437.25M
Total Liabilities	$633.31M
Common Equity	$-119.15M
Tangible Shareholders Equity	$-119.15M
Shareholders Equity	$-119.15M
Common Shares Outstanding	213.06M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$347.37M
Cash Flow from Investing Activities	$-13.69M
Cash Flow from Financial Activities	$-349.93M
Beginning Cash	$106.32M
End Cash	$91.34M
Increase/Decrease in Cash	$-14.99M
Stock-Based Compensation	$85.07M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.06
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.39
Debt to Equity Ratio	-4.05
Gross Margin	97.82%
Operating Margin	38.98%
EBIT Margin	38.98%
EBITDA Margin	38.64%
Pre-Tax Profit Margin	30.56%
Profit Margin	30.16%
Free Cash Flow	$345.45M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	1.70
Inventory Turnover	3.53
Receiveable Turnover	8.19
Days Sales in Receivables	44.57
Return on Equity	-221.45%
Return on Tangible Equity	-221.45%
Return on Assets	51.32%
Return on Investments	85.25%
Book Value Per Share	$-0.56
Free Cash Flow per Share	$1.58
Operating Cash Flow per Share	$1.59

Data from Zacks Investment Research, Inc.